Dragon’s Offer: Imparting Wisdom About Market Access Through the NRDL in China
Available On Demand
What do pharmaceutical manufacturers need to know to successfully navigate the market access landscape in China through the latest NRDL update?
The access landscape in China is rapidly evolving with important implications for novel medicines. The most recent update of China’s National Reimbursement Drug List (NRDL) in 2021 focused on the expansion of new and high-cost innovative therapies and highlighted the improving access environment for these drugs.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an overview of the market access landscape in China with an in-depth analysis of the 2021 NRDL. We will discuss the pricing implications needed to secure public funding in China, along with how to navigate key NRDL strategies.
The dragon is an important symbol in East Asian culture, representing wisdom and power. Join our experts as they impart knowledge to empower your market access strategies.
Trinity continues to explore this topic. Click on the links to read our past blog posts about market access opportunities for rare disease and oncology products in China based on the 2020 NRDL.
- Introduction to the NRDL and overview of the access landscape in China
- Key features of the 2021 NRDL update
- In-depth analysis of oncology and rare disease drug reimbursement